Matthew Hawryluk Net Worth

The estimated Net Worth of Matthew Hawryluk is at least $161 mil dollars as of 15 May 2024. Matthew Hawryluk owns over 9,259 units of Gritstone Bio Inc stock worth over $153,826 and over the last 6 years he sold GRTS stock worth over $6,944. In addition, he makes $0 as Executive Vice President e Chief Business Officer at Gritstone Bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Matthew Hawryluk GRTS stock SEC Form 4 insiders trading

Matthew has made over 1 trades of the Gritstone Bio Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 9,259 units of GRTS stock worth $6,944 on 15 May 2024.

The largest trade he's ever made was selling 9,259 units of Gritstone Bio Inc stock on 15 May 2024 worth over $6,944. On average, Matthew trades about 661 units every 0 days since 2019. As of 15 May 2024 he still owns at least 313,931 units of Gritstone Bio Inc stock.

You can see the complete history of Matthew Hawryluk stock trades at the bottom of the page.

Matthew Hawryluk biography

Dr. Matthew Hawryluk Ph.D. serves as Executive Vice President, Chief Business Officer of the Company. He has served as our Executive Vice President and Chief Business Officer since November 2015. Prior to Gritstone, from April 2011 to October 2015, Dr. Hawryluk held positions of increasing responsibility at Foundation Medicine, Inc., or Foundation Medicine, a public molecular diagnostics company, most recently serving as vice president, corporate and business development. Previously, he held roles in business development, marketing and product management across multiple divisions of Thermo Fisher Scientific, Inc. Dr. Hawryluk received a B.S. from the University of Notre Dame, a Ph.D. in cell biology and protein biochemistry from the University of Pittsburgh School of Medicine and an M.B.A. at Carnegie Mellon University’s Tepper School of Business as a Swartz Entrepreneurial Fellow.

How old is Matthew Hawryluk?

Matthew Hawryluk is 42, he's been the Executive Vice President e Chief Business Officer of Gritstone Bio Inc since 2015. There are 16 older and 3 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..

What's Matthew Hawryluk's mailing address?

Matthew's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.

Insiders trading at Gritstone Bio Inc

Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson, eThomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.

What does Gritstone Bio Inc do?

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Complete history of Matthew Hawryluk stock trades at Gritstone Bio Inc e Predictive Oncology

Gritstone Bio Inc executives and stock owners

Gritstone Bio Inc executives and other stock owners filed with the SEC include:

• Andrew Allen,
  President, Chief Executive Officer, Director
• Jean-Marc Bellemin,
  Chief Financial Officer, Executive Vice President
• Raphael Rousseau,
  Executive Vice President, Chief Medical Officer
• Karin Jooss,
  Executive Vice President - Research, Chief Scientific Officer
• Roman Yelensky,
  Executive Vice President, Chief Technology Officer
• Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.,
  Co-Founder, Pres, CEO & Director
• Erin E. Jones M.S.,
  Chief Operating Officer
• Steve Krognes,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Richard Heyman,
  Independent Director
• Judith Li,
  Independent Director
• Nicholas Simon,
  Independent Director
• Elaine Jones,
  Chairman of the Board
• Vijay Yabannavar,
  Executive Vice President, Manufacturing and Technical Operations
• Erin Jones,
  Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance
• Matthew Hawryluk,
  Executive Vice President, Chief Business Officer
• Alan C. Mendelson J.D.,
  Sec.
• Dr. Karin Jooss,
  Head of R&D
• Dr. Matthew Hawryluk,
  Exec. VP & Chief Bus. Officer
• Prof. Raphael F. Rousseau M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Stacy Proctor,
  Sr. VP & Head of People
• Rahsaan W. Thompson J.D.,
  Exec. VP & Gen. Counsel
• James Cho,
  Chief Accounting Officer
• Vassiliki Economides,
  Exec. VP & CFO
• Stephen W Webster,
  
• Group, Llc Green Jeremy Red...,
  
• Venture Capital V, L.P.Vers...,
  
• Peter Svennilson,
  Director
• Group Ii, Lp Column Group I...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Rahsaan Thompson,
  EVP and General Counsel
• Shefali Agarwal,
  
• Clare Fisher,
  
• Naiyer Rizvi,
  
• Lawrence Corey,
  
• James Cho,
  SVP, CHIEF ACCOUNTING OFFICER
• Vassiliki Economides,
  EVP, CHIEF FINANCIAL OFFICER